Findings

What do systematic reviews say?

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Benzbromarone vs allopurinol

Pain reduction ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs allopurinol

Function ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs allopurinol

Tophus regression ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ciprofloxacin vs fluoroquinolones

Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis

It is very uncertain whether ciprofloxacin changes clinical efficacy ‐ cure or improvement at end of treatment compared with comparator fluoroquinolone (very low certainty).

2 findings from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 0.9 [0.75, 1.08]
3 studies · 851 participants
Very low
Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 0.93 [0.72, 1.2]
3 studies · 851 participants
Very low

Ciprofloxacin vs fluoroquinolones

Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis

Ciprofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).

1 finding from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 1.16 [0.95, 1.42]
3 studies · 967 participants
Moderate

Levofloxacin vs fluoroquinolones

Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis

It is very uncertain whether levofloxacin changes microbiological efficacy ‐ pathogen eradication compared with comparator fluoroquinolone (very low certainty).

1 finding from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 1.12 [0.84, 1.48]
3 studies · 758 participants
Very low

Levofloxacin vs fluoroquinolones

Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis

2 findings from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Levofloxacin vs fluoroquinolones

Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis

Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).

1 finding from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 0.88 [0.72, 1.08]
3 studies · 874 participants
Moderate

Lomefloxacin vs fluoroquinolones

Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis

Lomefloxacin showed no clear difference in microbiological efficacy ‐ pathogen eradication at compared with comparator fluoroquinolone (low certainty).

1 finding from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 0.96 [0.8, 1.16]
2 studies · 116 participants
Low

Lomefloxacin vs fluoroquinolones

Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis

2 findings from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Lomefloxacin vs fluoroquinolones

Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis

Lomefloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).

1 finding from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 0.64 [0.34, 1.21]
2 studies · 215 participants
Moderate

Ciprofloxacin vs fluoroquinolones

Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis

It is very uncertain whether ciprofloxacin changes microbiological efficacy ‐ pathogen eradication at end of treatment compared with comparator fluoroquinolone (very low certainty).

1 finding from 1 review

Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
RR 0.91 [0.7, 1.18]
3 studies · 851 participants
Very low

Doxycycline+Rifampicin vs Quinolones+Rifampicin

total treatment failure · patients with human Brucellosis

Doxycycline+Rifampicin showed no clear difference in total treatment failure compared with quinolones+Rifampicin (moderate certainty).

1 finding from 1 review

Antibiotics for treating human brucellosis 2012 · Cochrane Headline outcomes only
OR 0.94 [0.45, 1.98]
3 studies · 181 participants
Moderate

Febuxostat 40 mg/day vs allopurinol

Acute gout attacks · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 0.97 [0.57, 1.65]
1 study · 1324 participants
High

Febuxostat 40 mg/day vs allopurinol

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.1 [0.94, 1.2]
1 study · 1324 participants
Moderate

Febuxostat 40 mg/day vs allopurinol

Pain · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Febuxostat 40 mg/day vs allopurinol

Patient global assessment · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Febuxostat 40 mg/day vs allopurinol

Health related quality of life · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Febuxostat 40 mg/day vs allopurinol

Serious adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 0.61 [0.35, 1.07]
1 study · 1513 participants
High

Febuxostat 40 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.2 [0.9, 1.7]
1 study · 1513 participants
High